genglob magazine

Icon

magazine by genglob.com for generics, medicines and alternative treatments like ayurveda and traditional chinese

Revlimid Meets Primary Endpoint In A Phase III Study

multiplemyeloma

The initial data from a Phase III study using the Revlimid in multiple myeloma patients who had undergone stem cell transplant reported that the trial had met its primary endpoint of a statistically significant improvement in time to disease progression. Read the rest of this entry »

  • Share/Bookmark